Chinese Regulator Approves Concord Healthcare's Application for Large-scale Deployment of Proton Therapy Equipment

MT Newswires Live09-16

Concord Healthcare Group's (HKG:2453) application for the license for the deployment of large-scale medical equipment for proton therapy was approved by the National Health Commission of China on Friday, Sept. 13, a Sunday filing with the Hong Kong Exchange said.

Guangzhou Concord Cancer Center, an 80% owned subsidiary of the company acquired one customized set of proton therapy equipment and had started clinical trials to test the equipment. The company had applied for the license to deploy large-scale proton therapy equipment on April 29.

Proton therapy is a type of radiation therapy for cancer in which the equipment directs a beam of protons directly to the tumor with a sub-millimeter precision while sparing nearby healthy tissues and minimizing side effects.

The oncology healthcare services provider intends to start the proton therapy operation as soon as it makes some required preparations.

The company's shares closed nearly 6% higher on Monday.

Price (HKD): $18.58, Change: $+1.0, Percent Change: +5.81%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2467816809?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-16 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2467816809","market":"us","top_or_hot":-1,"title":"Chinese Regulator Approves Concord Healthcare's Application for Large-scale Deployment of Proton Therapy Equipment","media":"MT Newswires Live","content":"<html><body><p> Concord Healthcare Group's (HKG:2453) application for the license for the deployment of large-scale medical equipment for proton therapy was approved by the National Health Commission of China on Friday, Sept. 13, a Sunday filing with the Hong Kong Exchange said.</p><p>Guangzhou Concord Cancer Center, an 80% owned subsidiary of the company acquired one customized set of proton therapy equipment and had started clinical trials to test the equipment. The company had applied for the license to deploy large-scale proton therapy equipment on April 29.</p><p>Proton therapy is a type of radiation therapy for cancer in which the equipment directs a beam of protons directly to the tumor with a sub-millimeter precision while sparing nearby healthy tissues and minimizing side effects.</p><p>The oncology healthcare services provider intends to start the proton therapy operation as soon as it makes some required preparations.</p><p>The company's shares closed nearly 6% higher on Monday.</p><p>Price (HKD): $18.58, Change: $+1.0, Percent Change: +5.81%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Regulator Approves Concord Healthcare's Application for Large-scale Deployment of Proton Therapy Equipment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Regulator Approves Concord Healthcare's Application for Large-scale Deployment of Proton Therapy Equipment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-16 19:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Concord Healthcare Group's (HKG:2453) application for the license for the deployment of large-scale medical equipment for proton therapy was approved by the National Health Commission of China on ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"应用软件","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2467816809","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467816809","pubTimestamp":1726484442,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Concord Healthcare Group's  application for the license for the deployment of large-scale medical equipment for proton therapy was approved by the National Health Commission of China on Friday, Sept. 13, a Sunday filing with the Hong Kong Exchange said.Guangzhou Concord Cancer Center, an 80% owned subsidiary of the company acquired one customized set of proton therapy equipment and had started clinical trials to test the equipment. The company had applied for the license to deploy large-scale proton therapy equipment on April 29.Proton therapy is a type of radiation therapy for cancer in which the equipment directs a beam of protons directly to the tumor with a sub-millimeter precision while sparing nearby healthy tissues and minimizing side effects.The oncology healthcare services provider intends to start the proton therapy operation as soon as it makes some required preparations.The company's shares closed nearly 6% higher on Monday.Price : $18.58, Change: $+1.0, Percent Change: +5.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4023":"应用软件","BK1209":"保健护理机构","02453":"美中嘉和","HCSG":"医疗保健服务","BK4137":"综合支持服务","CNDA":"Concord Acquisition Corp II","BK4585":"ETF&股票定投概念","BK4588":"碎股","HKD":"尚乘数科","BK4526":"热门中概股"},"translate_title":"中国监管机构批准协和医疗大规模部署质子治疗设备的申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNDA":1,"HCSG":1,"HKD":1,"02453":0.9},"content_text":"Concord Healthcare Group's (HKG:2453) application for the license for the deployment of large-scale medical equipment for proton therapy was approved by the National Health Commission of China on Friday, Sept. 13, a Sunday filing with the Hong Kong Exchange said.Guangzhou Concord Cancer Center, an 80% owned subsidiary of the company acquired one customized set of proton therapy equipment and had started clinical trials to test the equipment. The company had applied for the license to deploy large-scale proton therapy equipment on April 29.Proton therapy is a type of radiation therapy for cancer in which the equipment directs a beam of protons directly to the tumor with a sub-millimeter precision while sparing nearby healthy tissues and minimizing side effects.The oncology healthcare services provider intends to start the proton therapy operation as soon as it makes some required preparations.The company's shares closed nearly 6% higher on Monday.Price (HKD): $18.58, Change: $+1.0, Percent Change: +5.81%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2467816809"}